Seth Baum

Chief Medical Officer

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Seth Baum is the Chief Medical Officer at Flourish Research in the United States. His research focuses on patient experiences and clinical outcomes related to cardiovascular diseases and lipid disorders, as evidenced by his recent articles examining various treatments and patient responses. His work includes studies on familial chylomicronemia syndrome, heart failure management, and the impact of innovative therapies on lipid levels and cardiovascular health.

Articles (13)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Collaborators (3)

Christie M Ballantyne

Baylor College of Medicine

UNITED STATES

View details

Emily Bratlee-Whitaker

Health Solutions

UNITED STATES

View details

Sheldon Litwin

University of Utah

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Seth Baum

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants

Lipoprotein(a) levels in a population with clinical atherosclerotic cardiovascular disease in the United States: A subanalysis from the Lp(a)HERITAGE study

Trends in Patient Access to and Utilization of Prescribed PCSK9 Inhibitors in a Large US Claims Database From 2015 to 2021

Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

LIPOPROTEIN(A) LEVELS IN POPULATION WITH ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN THE UNITED STATES: A SUBANALYSIS FROM THE LP(A)HERITAGE STUDY

Non-medical switching an unmitigated threat to patient care

Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

BASELINE CARDIOVASCULAR RISK FOR PATIENTS WITH RECENT MYOCARDIAL INFARCTION PRESCRIBED A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR

BEMPEDOIC ACID 180 MG + EZETIMIBE 10 MG FIXED-DOSE COMBINATION VS EZETIMIBE ALONE OR PLACEBO IN PATIENTS WITH TYPE 2 DIABETES AND HYPERCHOLESTEROLEMIA

Collaborators (3)

Christie M Ballantyne

Emily Bratlee-Whitaker

Sheldon Litwin

Make your next move.